Masthead

nCounter®
Tumor Signaling 360 Panel

Masthead

Helping Your Research

As therapeutics that target tumor signaling evolve, a greater understanding of tumor signaling is required as well as a better understanding of the interactions of tumor cells with the tissue milieu. The Tumor Signaling 360 Panel is intended to play this exact role, enabling deeper profiling of the tumor that is complete, yet focused on signaling pathways of interest for targeted therapeutic development. Covering hundreds of genes involved in tumorigenesis, metastasis, and inflammation, the nCounter Tumor Signaling 360 Panel offers a holistic view of the biology of the tumor, microenvironment, and immune response with an emphasis on dysfunctional cell signaling in cancer.  It offers a holistic view of the biology of the tumor, microenvironment, and immune response with an emphasis on dysfunctional cell signaling in cancer.

  • Profile 40+ pathways involved in tumor biology, immune evasion, and remodeling of the microenvironment.
  • Identify targets for novel therapeutics
  • Understand the mechanism of action of targeted therapies
  • Determine the extent of anti-tumor immune response with the Tumor Inflammation Signature
  • Quantify the presence and relative abundance of 14 different immune cell types

Inspired by systems biology approaches to cancer research, NanoString’s 360 Series Panel Collection gives you a 360° view of gene expression by combining carefully-curated content involved in the biology of the tumor, microenvironment, and the immune response into a single holistic assay. Each panel contains the 18-gene Tumor Inflammation Signature (TIS) that measures a peripherally-suppressed, adaptive immune response and has been shown to correlate with response to checkpoint inhibitors.

tumor promotion inflammation illustration

How it Works

The nCounter 360 series of cancer gene expression panels have been developed to comprehensively profile the tumor, immune response, and microenvironment. Genes included in the Tumor Signaling 360 Panel are organized and linked to various advanced analysis modules to allow for efficient analysis of cell signaling pathways.

Advanced Analysis Modules available for Tumor Signaling 360:

  • Normalization
  • Quality Control
  • Individual Pathway Analysis
  • Cell Profiling
  • Differential Expression
  • Gene Set Analysis
  • Built-in compatibility for Panel-Plus and Protein Analysis

 

Panel Selection Tool

Find the gene expression panel for your research with easy to use panel pro

Find Your Panel

Product Information

Core Themes and Annotations
Tumor Inflammation Signature
Immune Cell Type Gene Coverage
Product Specifications
Catalog Information
Product Comparison
Core Themes and Annotations
Tumor Inflammation Signature

The Tumor Inflammation Signature includes 18 functional genes known to be associated with response to PD-1/PD-L1 inhibitors.

Includes four areas of Immune Biology: IFN-ү-responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance genes.

The tumor inflammation gene expression signature highlights the complex biology of the host immune microenvironment.

View publication and video.

  1. Ayers, Mark, et al. “IFN-y-related mRNA profile predicts clinical response to PD-1 blockade.” The Journal of Clinical Investigation 127.8 (2017).
Immune Cell Type Gene Coverage

Platform Specifications (*Does not apply to Prosigna® Breast Cancer Prognostic Gene Signature Assay (1))

Product Specifications
Catalog Information
Product Comparison

360 Series Product Comparison

Fully-annotated gene lists in Excel format are available for each of the 360 Panels. The table below compares the biology coverage of the 360 Panels across the tumor, microenvironment, and the immune response to that of the PanCancer Panels Collection.

Related Resources

See All Resources
Product Bulletin Tumor Signaling 360 Panel – Product Bulletin

Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response.

The addition of HER2-targeted agents to neoadjuvant chemotherapy has dramatically improved pathological complete response (pCR) rates in early-stage, HER2-positive breast cancer. Nonetheless, up to 50% of patients have residual disease after treatment, while others are likely overtreated.

Molecular risk markers related to local tumor recurrence at histological margin-free endoscopically resected early gastric cancers: A pilot study.

Local recurrences in early gastric cancers (EGCs) after complete endoscopic submucosal dissection (ESD) remain problematic. Here, we investigated the spatially sequential molecular changes in various cancer-related proteins along the axis of the histologically clear but recurrent resection margins (TRM) to determine the appropriate tumor-free margin distance and potential molecular risk markers related to local recurrence.

PAM50 Intrinsic Subtype Profiles in Primary and Metastatic Breast Cancer Show a Significant Shift toward More Aggressive Subtypes with Prognostic Implications.

Background: PAM50 breast cancer intrinsic subtyping adds prognostic information in early breast cancer; however, the role in metastatic disease is unclear. We aimed to identify PAM50 subtypes in primary tumors (PTs) and metastases to outline subtype changes and their prognostic role.

Skysphere

Contact Us

Have questions or simply want to learn more?

Contact our helpful experts and we’ll be in touch soon.

Contact Us